<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351101</url>
  </required_header>
  <id_info>
    <org_study_id>ROC2-17-014</org_study_id>
    <nct_id>NCT03351101</nct_id>
  </id_info>
  <brief_title>Clinical Study of Approved Contact Lenses</brief_title>
  <official_title>Clinical Study of Approved Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of Johnson &amp; Johnson Acuvue Vita (senofilcon C) soft contact lenses to the Bausch
      + Lomb Ultra (samfilcon A) soft contact lenses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      to compare the performance of currently marketed Johnson &amp; Johnson Acuvue Vita (senofilcon C)
      soft contact lenses to the currently marketed Bausch + Lomb Ultra (samfilcon A) soft contact
      lenses among adapted wearers of Acuvue Oasys soft contact lenses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">December 8, 2017</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, bilateral, d o u b l e - masked, 1-month study with two parallel groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Take home questionnaire</measure>
    <time_frame>1 month</time_frame>
    <description>The 100 point questionnaire will evaluate performance of the lenses based on subject responses.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Acuvue Vita</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contact Lense</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>contact lense</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acuvue Vita</intervention_name>
    <description>contact lense</description>
    <arm_group_label>Acuvue Vita</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultra</intervention_name>
    <description>contact lense</description>
    <arm_group_label>Ultra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be between the ages of 18 and 40 years old, inclusive, on the date the
             Informed Consent Form (ICF) is signed and have the capacity to provide voluntary
             informed consent.

          2. Subjects must be able to read, understand and provide written informed consent on the
             Institutional Review Board (IRB)/Ethics Committee (EC) approved ICF and provide
             authorization as appropriate for local privacy regulations.

          3. Subjects must be willing and able to comply with all treatment and follow-up/study
             procedures.

          4. Subjects must be correctable through spherocylindrical refraction to 32 letters (0.3
             logMAR) or better (distance, high contrast) in each eye.

          5. Subjects must have clear central corneas and be free of any anterior segment
             disorders.

          6. Subjects must be myopic and require contact lens sphere power correction from -0.50
             diopter (D) to -6.00 D (considering vertex distance adjustments in both eyes).

          7. Subjects must be habitual wearers of Johnson &amp; Johnson Acuvue Oasys single vision
             spherical soft contact lenses in each eye.

          8. Subjects must use a contact lens care regimen on a routine basis.

          9. Subjects must agree to wear their study lenses on a daily wear basis for the duration

        Exclusion Criteria:

          1. Subjects participating in any drug or device clinical investigation within two weeks
             prior to entry into this study and/or during the period of study participation

          2. Subjects who are women of childbearing potential (those who are not surgically
             sterilized or postmenopausal) are excluded from participation in the investigation if
             they meet any one of the following conditions:

               -  she is currently pregnant

               -  she plans to become pregnant during the study

               -  she is breastfeeding

          3. Subjects with any systemic disease currently affecting ocular health or which in the
             Investigator's opinion may have an effect on ocular health during the course of the
             study.

          4. Subjects using any systemic or topical medications that will, in the Investigator's
             opinion, affect ocular physiology or lens performance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>valeant Site 02</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 03</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 04</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 06</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 05</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 07</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 08</name>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <zip>64093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 09</name>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <zip>13850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 10</name>
      <address>
        <city>Powell</city>
        <state>Ohio</state>
        <zip>43065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 11</name>
      <address>
        <city>New Berlin</city>
        <state>Wisconsin</state>
        <zip>53151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

